ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AstraZeneca's Lynparza scores limited NICE backing for new first-line maintenance use
July 29, 2019With competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new recommendation—a couple of caveats notwithstanding.
Pharma Sources Insight January 2025
